For instance, in the case of NSCLC patients with MET exon 14 skipping, the development of MET tyrosine kinase inhibitors (TKIs), such as capmatinib and tepotinib, has shown remarkable efficacy in clinical trials [18,19,20]. This evidence concerns the gene MET and non-small cell lung carcinoma.